Bijal Shah, MD, MS

Healio spoke with Bijal Shah, MD, MS, about mantle cell lymphoma, highlighting practice-changing research, FDA approvals, challenges in the field and more.

“We have to convince pharma that this is still an important space to invest in,” Shah, associate professor in the malignant hematology department at Moffitt Cancer Center, said.

In this video series, he discussed:

updates to the SHINE trial, and its role in the treatment of mantle cell lymphoma;
findings of ZUMA-2 and how it impacts clinical practice;
early data from phase 2 trials that are important to keep an eye on;
drug development as the biggest challenge in mantle cell lymphoma and how to address it;
where research should focus, noting that there are many areas “where people can dig their teeth in”; and
how a diagnosis of mantle cell lymphoma impacts patient quality of life and how to address that as the oncologist.

References:

Tam CS, et al. N Engl J Med. 2018;doi:10.1056/NEJMoa1715519.
Wang M, et al. Abstract LBA7502. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Wang M, et al. N Engl J Med. 2020;doi:10.1056/NEJMoa1914347.

Disclosure:

Shah reports relationships with Adaptive Biotech, AstraZeneca, BeiGene, Bristol Myers Squibb/Celgene, Kite Pharma and Pharmascience.

Mantle Cell Lymphoma Video Perspectives

Bijal Shah, MD, MS

References:

Disclosure: